Hui-Ming Zeng

Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

BACKGROUND QY201 is a novel oral Janus kinase 1 and tyrosine kinase 2 inhibitor. OBJECTIVE To evaluate the efficacy of multiple QY201 doses in moderate-to-severe atopic dermatitis (AD), and to inform dose selection for phase 3 studies. METHODS In this phase 2, randomized, double-blind, placebo-controlled trial, 200...